Revance Therapeutics reported $13.86M in Gross Profit on Sales for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Adamas Pharmaceuticals ADMS:US 25.32M 3.88M
Aerie Pharmaceuticals AERI:US $ 21.41M 0.41M
ALKERMES ALKS:US 244.58M 6.01M
Bristol Myers Squibb BMY:US $ 9333M 81M
Coherus Biosciences CHRS:US $ 61.22M 9.72M
Eli Lilly And LLY:US $ 5342M 555.1M
Endo International Ordinary Shares ENDP:US $ 474.91M 74.51M
Flexion Therapeutics FLXN:US $ 17.6M 5.6M
Gw Pharmaceuticals GWPH:US $ 140.66M 2.86M
Horizon Pharma HZNP:US $ 785.35M 153.8M
JAZZ PHA JAZZ:US $ 692.89M 60.27M
Johnson & Johnson JNJ:US $ 16088M 343M
Merk MRK:US $ 10098M 1738M
Neurocrine Biosciences NBIX:US $ 291.8M 6M
Pacira Pharmaceuticals PCRX:US $ 93.07M 7.27M
Procter & Gamble PG:US $ 9973M 818M
Revance Therapeutics RVNC:US $ 13.86M 481K
Supernus Pharmaceuticals SUPN:US $ 130.38M 14.08M
Teva Pharmaceutical Industries TEVA:US $ 1898M 25M
Zogenix ZGNX:US $ 21.32M 3.75M